As reported here previously, Aviptadil from Israel’s NeuroRx, is undergoing Phase 2/3 trials in Israel and the US. The adapted treatment, now known as RLF-100, prevents Covid-19 replication and has already significantly improved the health of 15 emergency cases in the US.

https://www.neurorxpharma.com/press-releases/rlf-100-aviptadil-clinical-trial-showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells/